The estimated Net Worth of Paul Edward Kelly is at least 1.18 百万$ dollars as of 9 September 2024. Mr. Kelly owns over 25,000 units of Relmada Therapeutics Inc stock worth over 641,131$ and over the last 6 years he sold RLMD stock worth over 0$. In addition, he makes 535,812$ as Independent Director at Relmada Therapeutics Inc.
Paul has made over 13 trades of the Relmada Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of RLMD stock worth 64,750$ on 9 September 2024.
The largest trade he's ever made was buying 100,000 units of Relmada Therapeutics Inc stock on 14 May 2019 worth over 150,000$. On average, Paul trades about 9,870 units every 85 days since 2018. As of 9 September 2024 he still owns at least 212,295 units of Relmada Therapeutics Inc stock.
You can see the complete history of Mr. Kelly stock trades at the bottom of the page.
Paul Edward Kelly serves as Independent Director of the Company since November 2015. Mr. Kelly is also Chairman of the Compensation Committee, and a member of the Audit Committee. Mr. Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for over 25 years. He began as an equity analyst at Mabon Securities in 1993, and served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune magazine All Star Analyst team in 2000. Subsequently, since 2007 Mr. Kelly has engaged in consulting for both private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly has advised Spring Bank Pharmaceuticals, Inc. and VisionGate, Inc. Mr. Kelly holds an A.B. in Biochemistry from Brown University, from which he was graduated magna cum laude, Sigma Xi and Phi Beta Kappa. He attended the University of Rochester School of Medicine and received an MBA in Finance from the William E. Simon School at the University of Rochester. That Mr. Kelly brings over 25 years of biotechnology experience to our Board of Directors, having served in various executive-level positions over the course of his career, and that he has developed significant management and leadership skills relating to the pharmaceutical industry, led us to conclude that Mr. Kelly should serve as a director.
As the Independent Director of Relmada Therapeutics Inc, the total compensation of Paul Kelly at Relmada Therapeutics Inc is 535,812$. There are 5 executives at Relmada Therapeutics Inc getting paid more, with Sergio Traversa having the highest compensation of 1,236,360$.
Paul Kelly is 62, he's been the Independent Director of Relmada Therapeutics Inc since 2015. There are 4 older and 11 younger executives at Relmada Therapeutics Inc. The oldest executive at Relmada Therapeutics Inc is Charles Casamento, 75, who is the Independent Chairman of the Board.
Paul's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES,, FL, 33134.
Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over 1,379,052$ worth of Relmada Therapeutics Inc stock and bought 574,305 units worth 1,722,071$ . The most active insiders traders include Sergio Traversa、Charles J Casamento、Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of 54,221$. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth 394,800$.
relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
Relmada Therapeutics Inc executives and other stock owners filed with the SEC include: